Zydus Life shares rise 2% after USFDA nod for Eluxadoline tablets

Zydus Lifesciences shares rose nearly 2% to Rs 899.40 after receiving USFDA approval to manufacture Eluxadoline Tablets (75 mg & 100 mg) for IBS-D treatment. The company secured 180 days of shared generic drug exclusivity. Analysts set an average target price of Rs 1,066, indicating a 21% upside, though technical indicators suggest a bearish trend.